Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cellworks Group
South San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead clinical program, GBM-2 (a small molecule for glioblastoma multiforme), is in Phase I clinical trials. Cellworks shows promise in employing biosimulation to match therapies to individual patient profiles; clinical validation ongoing.
- Therapeutic areas
- ImmunologyEndocrinologyInfectious DiseasesNeurologyDermatologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Collaborates with research centers for clinical development
Beyond the preview
Go deeper on Cellworks Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellworks Group.